These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 32485838)

  • 21. Nonalcoholic fatty liver disease in children and adolescents - Relationship with Polycystic Ovary Syndrome.
    Abruzzese GA; Motta AB
    Curr Pharm Des; 2015; 21(35):5144-50. PubMed ID: 26412465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
    Lonardo A; Lugari S; Ballestri S; Nascimbeni F; Baldelli E; Maurantonio M
    Acta Diabetol; 2019 Apr; 56(4):385-396. PubMed ID: 30519965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Fang Z; Dou G; Wang L
    Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes.
    Fernandes GW; Bocco BMLC
    Curr Diabetes Rev; 2021; 17(7):e110320187539. PubMed ID: 33143628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease.
    Liu W; Baker SS; Baker RD; Zhu L
    Curr Drug Targets; 2015; 16(12):1301-14. PubMed ID: 25915484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetics of Nonalcoholic Fatty Liver Disease: A 2018 Update.
    Valenti LVC; Baselli GA
    Curr Pharm Des; 2018; 24(38):4566-4573. PubMed ID: 30659533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NAFLD and diabetes mellitus.
    Tilg H; Moschen AR; Roden M
    Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):32-42. PubMed ID: 27729660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
    Wiering L; Subramanian P; Hammerich L
    Cell Mol Gastroenterol Hepatol; 2023; 15(6):1277-1292. PubMed ID: 36828280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis.
    Wang M; Li L; Xu Y; Du J; Ling C
    Front Pharmacol; 2022; 13():958428. PubMed ID: 36313291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD).
    Subramanian P; Hampe J; Tacke F; Chavakis T
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
    Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
    J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Dharmalingam M; Yamasandhi PG
    Indian J Endocrinol Metab; 2018; 22(3):421-428. PubMed ID: 30090738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.